Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
BURLINGTON, Mass., March 12, 2026 -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.
| The Stifel 2026 Virtual CNS Forum |
|
| Format: | Company presentation |
| Day/Time: | Wednesday, March 18 at 8.30 AM ET |
| Webcast: | Webcast Link: |
If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Investor inquiries:
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Polkadot Change Could Strip Two Largest Barriers Facing DOT Stakers
CZ Joins Crypto Users Mocking Fake Web3 Job Scams
CoinUp Growth Hub Bangkok Ends Successfully, Linking SEA With Web3
Commodity Radar: Gold's bullish trend intact despite current consolidation. Buy for these targets
Trending news
MoreCrypto prices
More
